{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:28:33Z","timestamp":1793017713221,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.amjmed.2024.10.026","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:00:43Z","timestamp":1730739643000},"page":"387-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Diabetic Cardiomyopathy: What Clinicians Should Know"],"prefix":"10.1016","volume":"138","author":[{"given":"Hannah","family":"Smati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Kamran","family":"Qadeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Errol","family":"Moras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Marwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayakrit","family":"Krittanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.amjmed.2024.10.026_bib0001","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s00018-011-0690-x","article-title":"Subcellular trafficking of the substrate transporters GLUT4 and CD36 in cardiomyocytes","volume":"68","author":"Steinbusch","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"10.1016\/j.amjmed.2024.10.026_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165775","article-title":"Understanding the distinct subcellular trafficking of CD36 and GLUT4 during the development of myocardial insulin resistance","volume":"1866","author":"Luiken","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0003","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1152\/ajpendo.90306.2008","article-title":"Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology","volume":"295","author":"Karnieli","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.amjmed.2024.10.026_bib0004","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.lfs.2012.10.011","article-title":"Diabetic cardiomyopathy and metabolic remodeling of the heart","volume":"92","author":"Battiprolu","year":"2013","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.amjmed.2024.10.026_bib0005","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.amjmed.2024.10.026_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-016-0309-5","article-title":"PPARs modulate cardiac metabolism and mitochondrial function in diabetes","volume":"24","author":"Lee","year":"2017","journal-title":"J Biomed Sci"},{"issue":"13","key":"10.1016\/j.amjmed.2024.10.026_bib0007","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.96.13.7473","article-title":"A critical role for the peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) in the cellular fasting response: the PPAR\u03b1-null mouse as a model of fatty acid oxidation disorders","volume":"96","author":"Leone","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.amjmed.2024.10.026_bib0008","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12933-020-01188-0","article-title":"Impact of peroxisome proliferator-activated receptor-\u03b1 on diabetic cardiomyopathy","volume":"20","author":"Wang","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.amjmed.2024.10.026_bib0009","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000433","article-title":"Taking diabetes to heart\u2014deregulation of myocardial lipid metabolism in diabetic cardiomyopathy","volume":"2","author":"Bayeva","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"10.1016\/j.amjmed.2024.10.026_bib0010","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1161\/CIRCULATIONAHA.105.554360","article-title":"Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity","volume":"112","author":"Boudina","year":"2005","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.amjmed.2024.10.026_bib0011","doi-asserted-by":"crossref","first-page":"14783","DOI":"10.1016\/S0021-9258(18)33348-9","article-title":"Studies on the interaction of palmitoyl coenzyme A with the adenine nucleotide translocase","volume":"257","author":"Woldegiorgis","year":"1982","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.amjmed.2024.10.026_bib0012","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1152\/ajplegacy.1975.228.3.689","article-title":"Acyl-CoA inhibition of adenine nucleotide translocation in ischemic myocardium","volume":"228","author":"Shug","year":"1975","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1016\/j.amjmed.2024.10.026_bib0013","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","article-title":"Advanced glycation end products","volume":"114","author":"Goldin","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.amjmed.2024.10.026_bib0014","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/cells11081312","article-title":"Advanced glycation end-products (AGEs): formation, chemistry, classification, receptors, and diseases related to AGEs","volume":"11","author":"Twarda-Clapa","year":"2022","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.amjmed.2024.10.026_bib0015","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.amjhyper.2004.08.021","article-title":"Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease","volume":"17","author":"Cooper","year":"2004","journal-title":"Am J Hypertens"},{"issue":"8","key":"10.1016\/j.amjmed.2024.10.026_bib0016","doi-asserted-by":"crossref","first-page":"e72080","DOI":"10.1371\/journal.pone.0072080","article-title":"Cardiac fibroblast-dependent extracellular matrix accumulation is associated with diastolic stiffness in type 2 diabetes","volume":"8","author":"Hutchinson","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.amjmed.2024.10.026_bib0017","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4239\/wjd.v5.i6.860","article-title":"Molecular mechanisms of AGE\/RAGE-mediated fibrosis in the diabetic heart","volume":"5","author":"Zhao","year":"2014","journal-title":"World J Diabetes"},{"issue":"7","key":"10.1016\/j.amjmed.2024.10.026_bib0018","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.3390\/ijms23073587","article-title":"Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus","volume":"23","author":"Nakamura","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.amjmed.2024.10.026_bib0019","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/eurjhf\/hfr080","article-title":"AKT signalling in the failing heart","volume":"13","author":"Chaanine","year":"2011","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.amjmed.2024.10.026_bib0020","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1194\/jlr.M800147-JLR200","article-title":"Ceramide is a cardiotoxin in lipotoxic cardiomyopathy","volume":"49","author":"Park","year":"2008","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.amjmed.2024.10.026_bib0021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1096\/fba.2023-00139","article-title":"Cardiac lipotoxicity and fibrosis underlie impaired contractility in a mouse model of metabolic dysfunction-associated steatotic liver disease","volume":"6","author":"Badmus","year":"2024","journal-title":"FASEB Bioadv"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0022","doi-asserted-by":"crossref","DOI":"10.1080\/13510002.2023.2246720","article-title":"Oxidative stress signaling in the pathogenesis of diabetic cardiomyopathy and the potential therapeutic role of antioxidant naringenin","volume":"28","author":"Xu","year":"2023","journal-title":"Redox Rep"},{"issue":"5","key":"10.1016\/j.amjmed.2024.10.026_bib0023","doi-asserted-by":"crossref","first-page":"E685","DOI":"10.1152\/ajpendo.2001.280.5.E685","article-title":"Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE","volume":"280","author":"Wautier","year":"2001","journal-title":"Am J Phys\u2014Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.amjmed.2024.10.026_bib0024","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3892\/ijmm.2012.891","article-title":"ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells","volume":"29","author":"Hu","year":"2012","journal-title":"Int J Mol Med"},{"issue":"2","key":"10.1016\/j.amjmed.2024.10.026_bib0025","doi-asserted-by":"crossref","first-page":"E323","DOI":"10.1152\/ajpendo.00024.2008","article-title":"Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs","volume":"295","author":"Tikellis","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0026","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/cvr\/cvr212","article-title":"Lipotoxicity in type 2 diabetic cardiomyopathy","volume":"92","author":"van de Weijer","year":"2011","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.amjmed.2024.10.026_bib0027","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4239\/wjd.v4.i5.177","article-title":"Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management","volume":"4","author":"Pappachan","year":"2013","journal-title":"World J Diabetes"},{"key":"10.1016\/j.amjmed.2024.10.026_bib0028","article-title":"Prevalence and predictors of subclinical cardiomyopathy in patients with type 2 diabetes in a health system","author":"Nagori","year":"2023","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.amjmed.2024.10.026_bib0029","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.biopha.2018.11.086","article-title":"Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate","volume":"109","author":"Al Hroob","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"13","key":"10.1016\/j.amjmed.2024.10.026_bib0030","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.3390\/ijms20133264","article-title":"Molecular dysfunction and phenotypic derangement in diabetic cardiomyopathy","volume":"20","author":"Evangelista","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.amjmed.2024.10.026_bib0031","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.amjmed.2024.04.035","article-title":"Coronary microvascular dysfunction: a guide for clinicians","volume":"137","author":"Smati","year":"2024","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0032","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11154-012-9235-3","article-title":"Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide","volume":"14","author":"Symons","year":"2013","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"10.1016\/j.amjmed.2024.10.026_bib0033","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/HJH.0b013e328013e7dd","article-title":"Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension","volume":"25","author":"Zieman","year":"2007","journal-title":"J Hypertens"},{"issue":"27","key":"10.1016\/j.amjmed.2024.10.026_bib0034","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.amjmed.2024.10.026_bib0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14797\/mdcj-14-4-251","article-title":"Cardiac autonomic neuropathy in diabetes mellitus","volume":"14","author":"Agashe","year":"2018","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0036","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4239\/wjd.v5.i1.17","article-title":"Cardiac autonomic neuropathy in patients with diabetes mellitus","volume":"5","author":"Dimitropoulos","year":"2014","journal-title":"World J Diabetes"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0037","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4239\/wjd.v6.i1.80","article-title":"Diabetes and cardiac autonomic neuropathy: clinical manifestations, cardiovascular consequences, diagnosis and treatment","volume":"6","author":"Balc\u0131o\u011flu","year":"2015","journal-title":"World J Diabetes"},{"issue":"3","key":"10.1016\/j.amjmed.2024.10.026_bib0038","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10741-011-9257-z","article-title":"Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment","volume":"17","author":"Falc\u00e3o-Pires","year":"2012","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjmed.2024.10.026_bib0039","series-title":"Endotext","article-title":"Diabetes, cardiomyopathy, and heart failure","author":"Oktay","year":"2000"},{"issue":"2","key":"10.1016\/j.amjmed.2024.10.026_bib0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00059-011-3429-4","article-title":"Diabetic cardiomyopathy\u2014fact or fiction?","volume":"36","author":"Maisch","year":"2011","journal-title":"Herz"},{"key":"10.1016\/j.amjmed.2024.10.026_bib0041","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12933-017-0506-x","article-title":"Diagnostic approaches for diabetic cardiomyopathy","volume":"16","author":"Lorenzo-Almor\u00f3s","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10.1016\/j.amjmed.2024.10.026_bib0042","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jcmg.2018.03.015","article-title":"Diagnosis of nonischemic stage B heart failure in type 2 diabetes mellitus: optimal parameters for prediction of heart failure","volume":"11","author":"Wang","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.amjmed.2024.10.026_bib0043","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11886-013-0449-0","article-title":"Role of cardiac MRI in diabetes","volume":"16","author":"Shah","year":"2014","journal-title":"Curr Cardiol Rep"},{"issue":"12","key":"10.1016\/j.amjmed.2024.10.026_bib0044","article-title":"Myocardial extracellular volume fraction adds prognostic information beyond myocardial replacement fibrosis","volume":"12","author":"Yang","year":"2019","journal-title":"Circulation: Cardiovas Imaging"},{"issue":"9","key":"10.1016\/j.amjmed.2024.10.026_bib0045","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2337\/dc18-0324","article-title":"Poor glycemic control is associated with increased extracellular volume fraction in diabetes","volume":"41","author":"Al-Badri","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.amjmed.2024.10.026_bib0046","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.106.645614","article-title":"Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study","volume":"116","author":"McGavock","year":"2007","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.amjmed.2024.10.026_bib0047","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1161\/CIRCRESAHA.120.315899","article-title":"Metabolic and molecular imaging of the diabetic cardiomyopathy","volume":"126","author":"Peterson","year":"2020","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0048","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1067\/mnc.2001.120635","article-title":"Quantification of myocardial glucose utilization by PET and 1-carbon-11-glucose","volume":"9","author":"Herrero","year":"2002","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0049","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12872-018-0943-9","article-title":"The association between diabetes mellitus and reduction in myocardial glucose uptake: a population-based 18F-FDG PET\/CT study","volume":"18","author":"Hu","year":"2018","journal-title":"BMC Cardiovas Disord"},{"issue":"16","key":"10.1016\/j.amjmed.2024.10.026_bib0050","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jacc.2009.04.074","article-title":"Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging","volume":"54","author":"Rijzewijk","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.amjmed.2024.10.026_bib0051","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2967\/jnumed.119.226993","article-title":"Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04","volume":"60","author":"Varasteh","year":"2019","journal-title":"J Nucl Med"},{"issue":"15","key":"10.1016\/j.amjmed.2024.10.026_bib0052","first-page":"17195","article-title":"Noninvasive monitoring of early cardiac fibrosis in diabetic mice by [68Ga]Ga-DOTA-FAPI-04 PET\/CT imaging","volume":"9","author":"Lin","year":"2024","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0053","first-page":"479","article-title":"Carvedilol alleviates diabetic cardiomyopathy in diabetic rats","volume":"17","author":"Zheng","year":"2019","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0054","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2337\/diaclin.27.1.36","article-title":"Reexamining misconceptions about \u03b2-blockers in patients with diabetes","volume":"27","author":"McGill","year":"2009","journal-title":"Clin Diab"},{"issue":"9, suppl 1","key":"10.1016\/j.amjmed.2024.10.026_bib0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.amjcard.2004.01.020","article-title":"\u03b2-blockers in hypertension: is carvedilol different?","volume":"93","author":"Messerli","year":"2004","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2024.10.026_bib0056","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/BF00400718","article-title":"The ACE-inhibitor captopril improves myocardial perfusion in spontaneously diabetic (BB) rats","volume":"38","author":"R\u00f6sen","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2024.10.026_bib0057","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12967-022-03842-5","article-title":"Angiotensin- (1-7) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through NF-kB and MAPK pathways","volume":"21","author":"Chen","year":"2023","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0058","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13098-023-01064-3","article-title":"Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus","volume":"15","author":"Jin","year":"2023","journal-title":"Diabetol Metabol Syndr"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0059","article-title":"Spironolactone protects against diabetic cardiomyopathy in streptozotocin-induced diabetic rats","volume":"2018","author":"Liu","year":"2018","journal-title":"J Diabetes Res"},{"issue":"16","key":"10.1016\/j.amjmed.2024.10.026_bib0060","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjmed.2024.10.026_bib0061","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.amjmed.2024.10.026_bib0062","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.amjmed.2024.10.026_bib0063","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.026_bib0064","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12933-023-01816-5","article-title":"Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms","volume":"22","author":"Huang","year":"2023","journal-title":"Cardiovas Diabetol"},{"key":"10.1016\/j.amjmed.2024.10.026_bib0065","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.2147\/DDDT.S269514","article-title":"SGLT2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"10.1016\/j.amjmed.2024.10.026_bib0066","article-title":"Empagliflozin improves left ventricular diastolic function of db\/db mice","volume":"1866","author":"Moellmann","year":"2020","journal-title":"Biochim Biophys Acta (BBA)\u2014Mol Basis Dis"},{"key":"10.1016\/j.amjmed.2024.10.026_bib0067","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","article-title":"A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats","volume":"17","author":"Durak","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10.1016\/j.amjmed.2024.10.026_bib0068","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan\u20142022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"issue":"15","key":"10.1016\/j.amjmed.2024.10.026_bib0069","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2024.10.026_bib0070","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2147\/DDDT.S400249","article-title":"Glucagon-like peptide-1 receptor agonist protects against diabetic cardiomyopathy by modulating microRNA-29b-3p\/SLMAP","volume":"17","author":"Fang","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.amjmed.2024.10.026_bib0071","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1758-5996-6-29","article-title":"Effect of exenatide on the cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits and heart function in streptozotocin-induced diabetic rats","volume":"6","author":"Guo","year":"2014","journal-title":"Diabetol Metab Syndr"},{"issue":"1-2","key":"10.1016\/j.amjmed.2024.10.026_bib0072","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.bbrc.2015.09.179","article-title":"Exendin-4 attenuates cardiac hypertrophy via AMPK\/mTOR signaling pathway activation","volume":"468","author":"Zhou","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.amjmed.2024.10.026_bib0073","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00125-007-0719-8","article-title":"Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy","volume":"50","author":"Van Linthout","year":"2007","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.amjmed.2024.10.026_bib0074","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180103","article-title":"Atorvastatin reduces \u03b2-adrenergic dysfunction in rats with diabetic cardiomyopathy","volume":"12","author":"Carillion","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.amjmed.2024.10.026_bib0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00592-010-0180-x","article-title":"The diabetic cardiomyopathy","volume":"48","author":"Tarquini","year":"2011","journal-title":"Acta Diabetol"},{"issue":"11","key":"10.1016\/j.amjmed.2024.10.026_bib0076","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0735-1097(03)00403-0","article-title":"Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the strong heart study","volume":"41","author":"Liu","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"suppl_1","key":"10.1016\/j.amjmed.2024.10.026_bib0077","first-page":"S179","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024","volume":"47","year":"2023","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.amjmed.2024.10.026_bib0078","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/eurjhf\/hfq110","article-title":"Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome","volume":"12","author":"Kiencke","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.amjmed.2024.10.026_bib0079","first-page":"724","article-title":"Natriuretic peptide-based screening for pre\u2013heart failure in patients with type 2 diabetes across the United States","volume":"11","author":"Cunningham","year":"2023","journal-title":"JACC: Heart Fail"},{"issue":"3","key":"10.1016\/j.amjmed.2024.10.026_bib0080","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033448","article-title":"Natriuretic peptide-based screening to identify stage B heart failure in people with type 1 diabetes","volume":"13","author":"Horton","year":"2024","journal-title":"J Am Heart Assoc"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324006958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324006958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T12:48:32Z","timestamp":1753361312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934324006958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0002934324006958"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.10.026","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetic Cardiomyopathy: What Clinicians Should Know","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}